Schering AG, and Philogen S.r.l., have announced that Schering acquired exclusive worldwide development and marketing rights for an antibody-based therapeutic fusion protein from Philogen. It is expected to have the potential to treat solid tumors by triggering immunological mechanisms. Financial details were not disclosed. “We consider antibodies to have the potential for outstanding efficacy in Read more about Schering, Philogen Agree License Deal[…]